Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

BACKGROUND: Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Jouneau, Stéphane, Crestani, Bruno, Thibault, Ronan, Lederlin, Mathieu, Vernhet, Laurent, Valenzuela, Claudia, Wijsenbeek, Marlies, Kreuter, Michael, Stansen, Wibke, Quaresma, Manuel, Cottin, Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7690188/
https://ncbi.nlm.nih.gov/pubmed/33239000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-020-01528-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados